AIM (AIM ImmunoTech) Moat Score: 4/10 (As of Jun. 29, 2026)


AIM AIM ImmunoTech Inc AIM
33 GF Score
Price $0.31
GF Value $2.69
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech Moat Score?

AIM ImmunoTech AIM -12.18% 33 Moat Score is 4 as of Jun. 29, 2026. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.69 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,401 Biotechnology companies, AIM ImmunoTech ranks better than 88.79% on this metric.

AIM ImmunoTech has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

AIM ImmunoTech has Narrow Moat: AIM ImmunoTech Inc has a discernible but modest moat due to its focus on niche biotech products and ongoing R&D efforts. However, it lacks strong brand strength or significant regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes AIM ImmunoTech might have Narrow Moat - Discernible but modest moat.

AIM ImmunoTech  (AMEX:AIM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

AIM ImmunoTech Moat Score Related Terms

AIM vs RVPH, BOLT, ERNA: Moat Score Comparison

For the Biotechnology subindustry, AIM ImmunoTech's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM ImmunoTech Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Moat Score distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Moat Score falls into.


AIM
33GF Score
AIM ImmunoTech Inc AIM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
AIM ImmunoTech (AIM) has a Moat Score of 4 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, AIM ImmunoTech ranks #157 out of 1401 companies in the Biotechnology industry, placing it in the top 11.2%.
Is AIM ImmunoTech's Moat Score too high?
AIM ImmunoTech's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. AIM ImmunoTech's value of 4 is 100% above this industry median. Based on the distribution chart, AIM ImmunoTech ranks #157 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Moat Score compare to RVPH and BOLT?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #157 out of 1401 companies for Moat Score. This places AIM ImmunoTech in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. AIM ImmunoTech's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AIM ImmunoTech's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AIM ImmunoTech's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.69, compared to a current price of $0.31 — trading 88.4% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Moat Score is 4 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (AIM) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of $0.31 is trading 88.4% below its estimated GF Value™ of $2.69. GuruFocus considers AIM ImmunoTech to be Possible Value Trap.

Key valuation signals for AIM:

  • Moat Score: 4
  • GF Value™: $2.69 vs. price of $0.31 (88.4% below fair value)
  • GF Score™: 33/100 with 6 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1401)

No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM ImmunoTech Business Description

Other Exchanges 0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for AIM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price
$2.69
GF Value